PSC 833 induces apoptosis in drug-sensitive human leukemia cell line and modulates resistance to paclitaxel in its multidrug-resistant variant

Anticancer Research

Volumn 20, Issue 6 B, 2000, Pages 4627-4632

  Duraj, J ^a   Takacsova, X ^a   Sedlak, J ^a   Sulikova, M ^a   Hunakova, L ^a   Bies, J ^a   Chorvath, B ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Apoptosis; Cell cycle alterations; Cyclosporine analog PSC 833; HL 60 VCR (MDR 1) human leukemia cell lines; Multidrug resistant HL 60 ADR (MRP); Paclitaxel

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; DNA FRAGMENT; FAS ANTIGEN; FAS LIGAND; GLYCOPROTEIN P; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; VALSPODAR;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA CONTENT; DNA DETERMINATION; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL LINE; METAPHASE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CELL CYCLE; CYCLOSPORINS; DNA FRAGMENTATION; DNA, NEOPLASM; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; UP-REGULATION;

EID: 0034483993     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Analysis of the interaction of SDZ PSC 833 ([3′-Keto-Bmt1]-Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein
2. Resistance modification by PSC 833, a novel non-immunosuppressive cyclosporine
3. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells
4. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells
5. Alteration of the daunorubicin-triggered sphingomyelin-ceramide pathway and apoptosis in MDR cells: Influence of drug transport abnormalities
6. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein
7. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis
8. Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis
9. L overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells
10. Bcl2 is the guardian of microtubule integrity
11. L is phosphorylated in malignant cells following microtubule disruption
12. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL- 60 cells
13. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay
14. Resistance of human multidrug-resistant neoplastic cell lines to paclitaxel-induced-radio-sensitization is reduced by the nonimmunosuppressive cyclosporine analog SDZ PSC 833
15. Protein kinase inhibitor-induced alterations of drug uptake, cell cycle and surface antigen expression in human multidrug-resistant (Pgp and MRP) promyelocytic leukemia (HL-60) cells
16. Taxol: A novel investigational antimicrotubule agent
17. The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation
18. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis
19. Paclitaxel-resistant human ovarian cancer cells have mutant ß-tubulins that exhibit impaired paclitaxel-driven polymerization
20. Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells
21. Bax is required for neuronal death after trophic factor deprivation and during development
22. Bax deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis
23. J. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity
24. Involvement of the CD95(APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
25. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions